Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Recent Phase III trials reported that once daily 5% minoxidil foam significantly increased hair count in women with female pattern hair loss and was shown to be as effective as twice daily 2% minoxidil solution.

This article discusses the authors' concerns over the misinterpretation of studies linking smoking and frontal fibrosing alopecia, clarifying that neither study suggests smoking is protective against the condition.

This study found that facial papules and rosacea in patients with frontal fibrosing alopecia were linked to a greater need for oral treatment, with most cases involving postmenopausal women.

This study identified a recurrent mutation in the endothelin receptor type A associated with mandibulofacial dysostosis with alopecia, and proposed a mechanism involving increased ligand affinity due to structural changes.

This study reports that variable environmental factors, including dietary habits, may contribute to the increasing incidence and diverse clinical presentations of frontal fibrosing alopecia.

This study found that individuals with frontal fibrosing alopecia have increased odds of thyroid disease, lupus erythematous, vitiligo, and heart disease, supporting the consideration of FFA as a systemic disorder.

In this case report, a 22-year-old female was diagnosed with follicular Dowling-Degos disease based on clinical and histological findings, with symptoms including skin lesions confined to hair follicles. The report emphasizes the importance of differentiating this rare variant from similar conditions for proper management.

This study found that trichoscopy is an effective noninvasive technique for diagnosing frontal fibrosing alopecia, confirming its valuable role alongside traditional histopathological examination.

This study retrospectively analyzed 14 postmenopausal women with frontal fibrosing alopecia, noting that 57% experienced total eyebrow loss, and all received various steroid treatments, highlighting the importance of early diagnosis to potentially delay disease progression.

This report analyzed an FDA adverse event database and aimed to evaluate and describe post-finasteride syndrome potentially related to dutasteride, but it does not report new clinical findings.

This review discusses the current understanding of frontal fibrosing alopecia's pathogenesis, highlighting genetic susceptibility, immune response involvement, and possible links to steroid hormones, but reports no new clinical results.

This study from North-East India analyzed 21 cases of frontal fibrosing alopecia, noting a high prevalence in post-menopausal women and distinct histological features such as perifollicular lymphocytic infiltrate and hydropic degeneration.

Patients with Focal Dermal Hypoplasia often experience skin, nail, hair, and bone issues, and may benefit from calcium and vitamin D supplements.

This study reported that fibrosing alopecia in a pattern distribution can occur in patients of color, with clinical and histopathological features allowing for an accurate differential diagnosis.

This study found that FGF5 alternative spliceosomes inhibit dermal papilla cell proliferation and regulate hair follicle growth-related gene expression, impacting hair follicle development in rabbits.

In this study, researchers created a coamorphous system combining tadalafil and finasteride that demonstrated improved solubility, dissolution, and stability compared to their physical mixture, offering potential therapeutic advantages for benign prostatic hyperplasia.

A male patient developed frontal fibrosing alopecia after antiandrogen therapy for prostate cancer.

This review discusses the non-follicular skin manifestations of frontal fibrosing alopecia and how they affect diagnosis and treatment, but reports no new clinical results.

Finasteride helps treat frontal fibrosing alopecia, improving or stabilizing the condition in many patients.

This review highlights available treatments for frontal fibrosing alopecia, noting that 5-alpha reductase inhibitors, intralesional steroids, and hydroxychloroquine currently have the most evidence supporting their use, while other treatments show variable results and require further study.

This review discusses frontal fibrosing alopecia in males and reports no new clinical results, indicating a broader demographic affected by this inflammatory disorder beyond postmenopausal women.

This preliminary study found that Melandrium firmum extract may promote hair growth and inhibit 5α-reductase, suggesting potential as a candidate for treating androgenetic alopecia.

In this study, Fgf20 was found to trigger movement and morphogenesis in dermal fibroblasts, facilitating dermal condensate formation essential for hair follicle development.

Farudodstat may help treat alopecia areata by protecting hair follicles.

In this in-vitro study, researchers identified finasteride as the most effective FDA-approved drug for expanding functional myeloid-derived suppressor cells, suggesting its potential future use in immunosuppressive therapies.

In this study, XZYFD, a Traditional Chinese Medicine formulation, was found to improve androgenetic alopecia in a testosterone-induced mouse model by promoting hair regrowth, restoring follicular morphology, and modulating androgen metabolism, MAPK signaling, and lipid metabolism pathways, suggesting potential benefits for patients with metabolic dysfunction.

This review discusses frontal fibrosing alopecia and reports no new clinical results; the authors highlight the need for randomized controlled trials on 5AR inhibitors to assess their efficacy and safety.

This study reports a case of a 59-year-old female with refractory follicular mucinosis and diffuse scalp alopecia who achieved complete clinical remission following treatment with a combination of topical tacalcitol and photodynamic therapy.

This study found that knocking down SFRP2 in an AGA model improved hair regeneration and reduced cellular dysfunction, suggesting that targeting the SFRP2-FSTL1 axis could be a promising therapeutic strategy for androgenetic alopecia.